NCT05651672

Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations

A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations That Failed Standard Therapy

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Tianjin Medical University Cancer Institute and Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is a prospective single-arm phase II study to evaluate the efficacy and safety of Pemigatinib in the advanced gastrointestinal cancer with FGFR 1-3 alterations and failed standard therapy.

Conditions

• Gastrointestinal Cancer

Interventions

Type	Name	Description
DRUG	Pemigatinib	13.5mg, po, 2 weeks on/1 week off, Q3W

Timeline

• Start date: 2022-12-02
• Primary completion: 2024-12-01
• Completion: 2026-12-01
• First posted: 2022-12-15
• Last updated: 2022-12-15

Locations

1 site across 1 country: China